Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have said this before, just as Harry Lander commented that NR2F6 will be huge!!!
http://www.cell.com/cell-reports/abstract/S2211-1247(15)00920-1
Hopefully it is!
At the moment PPS does not reflect true value but when Hemaxellerate (not counting other technologies) is approved (which will not take long, unlike what others have claimed) this will never be at this level. Provenge jumped to $70 overnight after FDA approved.
NR2F6 NCATS assay will be a major medical breakthrough!
http://www.cell.com/cell-reports/abstract/S2211-1247(15)00920-1
Good to see you here pistol pete, this stock just cought my eye and I really believe this might have great potential.
Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.
I also agree, let's see what unfolds... maybe in the future a class action lawsuit maybe needed
Shorts and flippers are holding this down we need big news (which is coming this week) and big money to squeeze our money back!
I'm looking forward to the same for my 401k. I do believe that things will move much faster now!
I'm just speculating but I believe that they wanted to include NIH funding.
Thanks ctvette, I haven't time to catch up yesterday. I did skim over posts and noticed the usual negative posts. I believe that things are better than ever with Regen and I believe that only great things coming our way very soon!!!
10k is out
http://www.sec.gov/Archives/edgar/data/1589150/000160706215000569/rgbp093015formnt.htm
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR
o Form N-CSR
For period ended:
September 30 , 2015
o Transition Report on Form 10-K
o Transition Report on Form 20-F
o Transition Report on Form 11-K
o Transition Report on Form 10-Q
o Transition Report on Form N-SAR
For the Transition Period Ended: N/A
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
Regen Biopharma, Inc.
Full Name of Registrant
Former Name if Applicable
4700 Spring Street, Suite 304
Address of Principal Executive Office (Street and Number)
La Mesa, CA 91942
City, State and Zip Code
--------------------------------------------------------------------------------
PART II - RULES 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached, if applicable.
PART III - NARRATIVE
The Company could not complete the filing of its Annual Report on Form 10-K for the period ended September 30, 2015 due to a delay in completion of the independent audit of the financial statements required to be included in the Company's Form 10-K, which delay could not be eliminated by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form 10-K no later than the fifteenth calendar day following the prescribed due date.
PART IV - OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification:
David Koos (619) 702-1404
(Name) (Area Code) (Telephone Number)
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes x No o
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes o No x
--------------------------------------------------------------------------------
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
Regen Biopharma, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 29, 2015 By: /s/ David Koos
David Koos
Chief Executive Officer
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
You are right L&L, a contract with NIH is huge! An assay used to take a human 12 years to complete the NIH robotics system now only takes a week to complete!!!
I believe dividend and Dcellvax human clinical trials are on deck!
interesting how these companies and doctors come together...
http://www.firstwordpharma.com/node/949957?tsid=17#axzz3vjD70M2G
What happened to post 22750
Merry Christmas to you and everyone else here
Also this is for those who go on and on and on and claim that NIH does not offer money are completely wrong.
"NCATS offers an array of funding programs and in-kind support services designed to help researchers translate basic scientific knowledge into interventions that improve human health".
http://irp.nih.gov/catalyst/v23i6/news-you-can-use
Thanks for the excellent DD!
It's interesting is that orphan drugs also pop up
go to NIH.GOV then type HEMAXELLERATE in the search box and see what you get
http://search.nih.gov/search?utf8=%E2%9C%93&affiliate=nih&query=hemaxellerate&commit=Search
Lol, I do feel very confident that great things are coming our way!
Right with you!
Like some said on here, great things coming our way!
I believe tomorrow will be Tuesday Koosday Newsday!
Hmm... interesting...
That's what happened with benitec
I don't know but believe it would be a good move if they have other good news to follow
I believe dividend news next week!
http://www.nih.gov/about-nih/what-we-do/impact-nih-research
"NIH is the largest public funder of biomedical research in the world, investing more than $30 billion in taxpayer dollars to achieve its mission to enhance health, lengthen life, and reduce illness and disability. In pursuing this mission, NIH improves health by promoting treatment and prevention, contributes to society by driving economic growth and productivity, and expands the biomedical knowledge base by funding cutting-edge research and cultivating the biomedical workforce of today and tomorrow."
I really hope so also. I must admit I am disapointed, other with much less have been at a much higher PPS. However I do believe things are looking up from now on.
Thanks gm
Yes I believe so
Approval not prove, apologize on my cell phone
Because of the time. Between prove and NIH agreement